These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 26551546)

  • 1. Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models.
    Busche MA; Grienberger C; Keskin AD; Song B; Neumann U; Staufenbiel M; Förstl H; Konnerth A
    Nat Neurosci; 2015 Dec; 18(12):1725-7. PubMed ID: 26551546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse models reveal why Alzheimer's treatment fails.
    Niemeyer JE
    Lab Anim (NY); 2016 Apr; 45(4):125. PubMed ID: 27003340
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment of amyloid-β₁₋₄₂-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice.
    Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C
    Neurobiol Aging; 2015 Jan; 36(1):111-22. PubMed ID: 25085784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer disease. Could anti-amyloid-β immunotherapy do more harm than good?
    Wood H
    Nat Rev Neurol; 2016 Jan; 12(1):2. PubMed ID: 26610710
    [No Abstract]   [Full Text] [Related]  

  • 6. [Current trend of immunotherapy for Alzheimer's disease].
    Matsumoto SE; Tabira T
    Nihon Rinsho; 2011 Sep; 69(9):1628-32. PubMed ID: 21922765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice.
    Wilcock DM; Colton CA
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):50-64. PubMed ID: 19275636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody against C-terminal Abeta selectively elevates plasma Abeta.
    Gray AJ; Sakaguchi G; Shiratori C; Becker AG; LaFrancois J; Aisen PS; Duff K; Matsuoka Y
    Neuroreport; 2007 Feb; 18(3):293-6. PubMed ID: 17314674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgenic expression of β1 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice.
    Paganetti P; Reichwald J; Bleckmann D; Abramowski D; Ammaturo D; Barske C; Danner S; Molinari M; Müller M; Papin S; Rabe S; Schmid P; Staufenbiel M
    Neurobiol Aging; 2013 Dec; 34(12):2866-78. PubMed ID: 23870837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?
    Panza F; Lozupone M; Dibello V; Greco A; Daniele A; Seripa D; Logroscino G; Imbimbo BP
    Immunotherapy; 2019 Jan; 11(1):3-6. PubMed ID: 30702009
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy.
    Nitsch RM; Hock C
    Neurotherapeutics; 2008 Jul; 5(3):415-20. PubMed ID: 18625453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease.
    Murakami K
    Biosci Biotechnol Biochem; 2014; 78(8):1293-305. PubMed ID: 25130729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part I.
    Agadjanyan MG; Cribbs DH
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):1-6. PubMed ID: 19275632
    [No Abstract]   [Full Text] [Related]  

  • 15. [Aβ immunotherapy for Alzheimer's disease].
    Sakai K; Yamada M
    Brain Nerve; 2013 Apr; 65(4):461-8. PubMed ID: 23568994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease.
    Fukuchi K; Tahara K; Kim HD; Maxwell JA; Lewis TL; Accavitti-Loper MA; Kim H; Ponnazhagan S; Lalonde R
    Neurobiol Dis; 2006 Sep; 23(3):502-11. PubMed ID: 16766200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Alzheimer's disease: the beginning of a new era.
    Schenk D
    Curr Alzheimer Res; 2006 Jul; 3(3):177. PubMed ID: 16842091
    [No Abstract]   [Full Text] [Related]  

  • 18. Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.
    Cehlar O; Skrabana R; Revajova V; Novak M
    Bratisl Lek Listy; 2018; 119(4):201-204. PubMed ID: 29663816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease.
    Solomon B
    Rejuvenation Res; 2008 Apr; 11(2):349-57. PubMed ID: 18341423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
    Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.